{"altmetric_id":4835329,"counts":{"readers":{"mendeley":18,"citeulike":0,"connotea":0},"total":{"posts_count":24},"news":{"unique_users_count":2,"unique_users":["medscape","biermann_medizin"],"posts_count":2},"twitter":{"unique_users_count":15,"unique_users":["BelgianOncology","AntonioGomezC4","JoaquinJCabrera","RRI_Research","ASCO","PBMangu","DrJLeeIR","DavidGrew","TrueDiagnostics","mtmdphd","subatomicdoc","Nani6016","Rad_Nation","roentgen66","HPB_surgery"],"posts_count":18},"facebook":{"unique_users_count":1,"unique_users":["1389966547980000"],"posts_count":1},"googleplus":{"unique_users_count":2,"unique_users":["\u4e2d\u6751\u592a\u7950","Radiosurgical Research Institute"],"posts_count":2},"f1000":{"unique_users_count":1,"unique_users":["F1000Prime"],"posts_count":1}},"selected_quotes":["Here is the article: @UMHealthSystem research by @DanWahlMD and @MaryFengMD #radonc #hpbcsm","@BluePriyaramesh Hi - here is the link. Let me know if you have trouble #radonc","If you need the article, it's free for #radonc journal club ending today","Outcomes After SBRT or RFA for Hepatocellular Carcinoma Wahl et al. #JCO #hpbcsm #radonc"],"citation":{"abstract":"Data guiding selection of nonsurgical treatment of hepatocellular carcinoma (HCC) are lacking. We therefore compared outcomes between stereotactic body radiotherapy (SBRT) and radiofrequency ablation (RFA) for HCC.\nFrom 2004 to 2012, 224 patients with inoperable, nonmetastatic HCC underwent RFA (n = 161) to 249 tumors or image-guided SBRT (n = 63) to 83 tumors. We applied inverse probability of treatment weighting to adjust for imbalances in treatment assignment. Freedom from local progression (FFLP) and toxicity were retrospectively analyzed.\nRFA and SBRT groups were similar with respect to number of lesions treated per patient, type of underlying liver disease, and tumor size (median, 1.8 v 2.2 cm in maximum diameter; P = .14). However, the SBRT group had lower pretreatment Child-Pugh scores (P = .003), higher pretreatment alpha-fetoprotein levels (P = .04), and a greater number of prior liver-directed treatments (P < .001). One- and 2-year FFLP for tumors treated with RFA were 83.6% and 80.2% v 97.4% and 83.8% for SBRT. Increasing tumor size predicted for FFLP in patients treated with RFA (hazard ratio [HR], 1.54 per cm; P = .006), but not with SBRT (HR, 1.21 per cm; P = .617). For tumors \u2265 2 cm, there was decreased FFLP for RFA compared with SBRT (HR, 3.35; P = .025). Acute grade 3+ complications occurred after 11% and 5% of RFA and SBRT treatments, respectively (P = .31). Overall survival 1 and 2 years after treatment was 70% and 53% after RFA and 74% and 46% after SBRT.\nBoth RFA and SBRT are effective local treatment options for inoperable HCC. Although these data are retrospective, SBRT appears to be a reasonable first-line treatment of inoperable, larger HCC.","altmetric_jid":"4f6fa5e93cf058f610005a18","authors":["Daniel R. Wahl","Matthew H. Stenmark","Yebin Tao","Erqi L. Pollom","Elaine M. Caoili","Theodore S. Lawrence","Matthew J. Schipper","Mary Feng","Wahl, Daniel R","Stenmark, Matthew H","Tao, Yebin","Pollom, Erqi L","Caoili, Elaine M","Lawrence, Theodore S","Schipper, Matthew J","Feng, Mary"],"doi":"10.1200\/jco.2015.61.4925","first_seen_on":"2015-12-03T04:02:48+00:00","funders":["niehs","nci"],"issns":["1527-7755","0732-183X"],"issue":"5","journal":"Journal of Clinical Oncology","last_mentioned_on":1465560568,"links":["http:\/\/jco.ascopubs.org\/content\/early\/2015\/11\/30\/JCO.2015.61.4925.short?rss=1","http:\/\/jco.ascopubs.org\/content\/early\/2015\/11\/30\/JCO.2015.61.4925?cmpid=jco_pap_1Dec2015#.VmGJtJZOo94.twitter","http:\/\/jco.ascopubs.org\/content\/early\/2015\/11\/30\/JCO.2015.61.4925.abstract","http:\/\/dx.doi.org\/10.1200\/JCO.2015.61.4925","http:\/\/jco.ascopubs.org\/content\/early\/2015\/11\/30\/JCO.2015.61.4925.abstract?utm_content=bufferd4ac8&utm_medium=social&utm_source=plus.google.com&utm_campaign=buffer","http:\/\/jco.ascopubs.org\/content\/34\/5\/452.short?rss=1","http:\/\/jco.ascopubs.org\/content\/34\/5\/452.abstract","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26628466","http:\/\/jco.ascopubs.org\/content\/34\/5\/452.full","http:\/\/jco.ascopubs.org\/content\/34\/5\/452.full?utm_content=buffer728b7&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer","http:\/\/m.jco.ascopubs.org\/content\/34\/5\/452.full","http:\/\/jco.ascopubs.org\/content\/34\/5\/452.full.pdf%20html","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26628466?dopt=Abstract&utm_source=dlvr.it&utm_medium=twitter"],"pdf_url":"http:\/\/jco.ascopubs.org\/content\/early\/2015\/11\/30\/JCO.2015.61.4925.full.pdf","pmid":"26628466","pubdate":"2015-12-03T22:00:55+00:00","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Biochemistry, Genetics and Molecular Biology"],"subjects":["neoplasms"],"title":"Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma","type":"article","volume":"34","mendeley_url":"http:\/\/www.mendeley.com\/research\/outcomes-after-stereotactic-body-radiotherapy-radiofrequency-ablation-hepatocellular-carcinoma"},"altmetric_score":{"score":28.15,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":28.15},"context_for_score":{"all":{"total_number_of_other_articles":7879571,"mean":6.6725285125901,"rank":282032,"this_scored_higher_than_pct":96,"this_scored_higher_than":7597357,"rank_type":"exact","sample_size":7879571,"percentile":96},"similar_age_3m":{"total_number_of_other_articles":294411,"mean":8.8175270337283,"rank":15691,"this_scored_higher_than_pct":94,"this_scored_higher_than":278709,"rank_type":"exact","sample_size":294411,"percentile":94},"this_journal":{"total_number_of_other_articles":8376,"mean":13.640835343284,"rank":829,"this_scored_higher_than_pct":90,"this_scored_higher_than":7546,"rank_type":"exact","sample_size":8376,"percentile":90},"similar_age_this_journal_3m":{"total_number_of_other_articles":202,"mean":21.708417910448,"rank":44,"this_scored_higher_than_pct":78,"this_scored_higher_than":158,"rank_type":"exact","sample_size":202,"percentile":78}}},"demographics":{"poster_types":{"member_of_the_public":10,"researcher":1,"practitioner":2,"science_communicator":2},"users":{"twitter":{"cohorts":{"Members of the public":10,"Science communicators (journalists, bloggers, editors)":2,"Practitioners (doctors, other healthcare professionals)":2,"Scientists":1}},"mendeley":{"by_status":{"Professor > Associate Professor":2,"Researcher":3,"Student  > Doctoral Student":1,"Student  > Ph. D. Student":3,"Student  > Postgraduate":1,"Other":5,"Student  > Bachelor":2,"Lecturer":1},"by_discipline":{"Medicine and Dentistry":15,"Physics and Astronomy":2,"Unspecified":1}}},"geo":{"twitter":{"ES":3,"US":7},"mendeley":{"US":1}}},"posts":{"f1000":[{"title":"Recommended in F1000 Prime","url":"https:\/\/f1000.com\/prime\/725979903","license":"public","citation_ids":[4835329],"posted_on":"2015-12-22T00:00:00+00:00","f1000_classes":["new_finding"],"f1000_score":"2"}],"twitter":[{"url":"http:\/\/twitter.com\/BelgianOncology\/statuses\/672264625568612352","license":"gnip","citation_ids":[4835329],"posted_on":"2015-12-03T04:02:31+00:00","author":{"name":"BelgianOncologyNews","image":"https:\/\/pbs.twimg.com\/profile_images\/471951016510779392\/0MOxYVeN_normal.png","id_on_source":"BelgianOncology","tweeter_id":"2524545985","geo":{"lt":null,"ln":null},"followers":239},"tweet_id":"672264625568612352"},{"url":"http:\/\/twitter.com\/AntonioGomezC4\/statuses\/672757337489326080","license":"gnip","citation_ids":[4835329],"posted_on":"2015-12-04T12:40:23+00:00","author":{"name":"Antonio G. C.","image":"https:\/\/pbs.twimg.com\/profile_images\/615770216279072769\/HM4LF2cP_normal.jpg","description":"El ejemplo es el \u00fanico argumento v\u00e1lido en la vida civil (Edmund Burke)","id_on_source":"AntonioGomezC4","tweeter_id":"3350685418","geo":{"lt":42.88052,"ln":-8.54569,"country":"ES"},"followers":224},"tweet_id":"672757337489326080"},{"url":"http:\/\/twitter.com\/JoaquinJCabrera\/statuses\/672823666024034304","license":"gnip","rt":["AntonioGomezC4"],"citation_ids":[4835329],"posted_on":"2015-12-04T17:03:57+00:00","author":{"id_on_source":"JoaquinJCabrera","tweeter_id":"733451022","geo":{"lt":38.87789,"ln":-6.97061,"country":"ES"}},"tweet_id":"672823666024034304"},{"url":"http:\/\/twitter.com\/RRI_Research\/statuses\/673871631282925569","license":"gnip","citation_ids":[4835329],"posted_on":"2015-12-07T14:28:11+00:00","author":{"name":"RadiosurgeryResearch","url":"http:\/\/www.rri-us.org","image":"https:\/\/pbs.twimg.com\/profile_images\/604376344596746240\/3XCFHvey_normal.png","description":"RRI is committed to improving the treatment outcomes of cancer patients and advancing radiosurgery through quality research with treatment centers worldwide","id_on_source":"RRI_Research","tweeter_id":"3303114737","geo":{"lt":"36.1622257","ln":"-86.7743419","country":"US"},"followers":49},"tweet_id":"673871631282925569"},{"url":"http:\/\/twitter.com\/ASCO\/statuses\/674695232907276288","license":"gnip","citation_ids":[4835329],"posted_on":"2015-12-09T21:00:53+00:00","author":{"name":"ASCO","url":"http:\/\/www.asco.org","image":"https:\/\/pbs.twimg.com\/profile_images\/463779450388090880\/UsaXUpTx_normal.png","description":"ASCO is the American Society of Clinical Oncology. Making a world of difference in cancer care.","id_on_source":"ASCO","tweeter_id":"20187065","geo":{"lt":38.80484,"ln":-77.04692,"country":"US"},"followers":69114},"tweet_id":"674695232907276288"},{"url":"http:\/\/twitter.com\/PBMangu\/statuses\/674991084221648897","license":"gnip","rt":["ASCO"],"citation_ids":[4835329],"posted_on":"2015-12-10T16:36:29+00:00","author":{"name":"Pamela Mangu","image":"https:\/\/pbs.twimg.com\/profile_images\/535850723607453696\/FsZUEWBg_normal.jpeg","id_on_source":"PBMangu","tweeter_id":"2887110497","geo":{"lt":null,"ln":null},"followers":17},"tweet_id":"674991084221648897"},{"url":"http:\/\/twitter.com\/DrJLeeIR\/statuses\/675032745802862593","license":"gnip","rt":["ASCO"],"citation_ids":[4835329],"posted_on":"2015-12-10T19:22:02+00:00","author":{"name":"Justin Lee","url":"http:\/\/www.floridainterventionalspecialists.com","image":"https:\/\/pbs.twimg.com\/profile_images\/800097443245420544\/_-aAsrcI_normal.jpg","description":"community interventional oncology, father of 3 boys, bearded and tattooed","id_on_source":"DrJLeeIR","tweeter_id":"20622959","geo":{"lt":27.33643,"ln":-82.53065,"country":"US"},"followers":423},"tweet_id":"675032745802862593"},{"url":"http:\/\/twitter.com\/DavidGrew\/statuses\/677816115683282944","license":"gnip","rt":["RRI_Research"],"citation_ids":[4835329],"posted_on":"2015-12-18T11:42:09+00:00","author":{"name":"David Grew","url":"http:\/\/www.stfranciscare.org\/physiciandirectory\/physiciandetail.aspx?ref=2997","image":"https:\/\/pbs.twimg.com\/profile_images\/658659260994297856\/t3XFVeR6_normal.jpg","description":"Radiation Oncologist at St Francis Hospital. Tulane MD MPH; NYU #radonc.","id_on_source":"DavidGrew","tweeter_id":"361633780","geo":{"lt":41.76371,"ln":-72.68509,"country":"US"},"followers":61},"tweet_id":"677816115683282944"},{"url":"http:\/\/twitter.com\/TrueDiagnostics\/statuses\/694684208082583552","license":"gnip","citation_ids":[4835329],"posted_on":"2016-02-03T00:49:56+00:00","author":{"name":"Jerry Lee","url":"http:\/\/www.truediag.com","image":"https:\/\/pbs.twimg.com\/profile_images\/567483990097936384\/6uKJglvi_normal.jpeg","description":"We specialize in providing quick & simple quantitative test systems designed for point-of-care monitoring. Test results in minutes not days..","id_on_source":"TrueDiagnostics","tweeter_id":"317232537","geo":{"lt":32.71533,"ln":-117.15726,"country":"US"},"followers":378},"tweet_id":"694684208082583552"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/699278308211613697","license":"gnip","citation_ids":[4835329],"posted_on":"2016-02-15T17:05:15+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15404},"tweet_id":"699278308211613697"},{"url":"http:\/\/twitter.com\/subatomicdoc\/statuses\/723868161808826368","license":"gnip","citation_ids":[4835329],"posted_on":"2016-04-23T13:36:33+00:00","author":{"name":"Matthew Katz, MD","url":"http:\/\/www.subatomicdoc.com","image":"https:\/\/pbs.twimg.com\/profile_images\/1243747643\/Dr_Katz2_normal.jpg","description":"I'm a radiation doctor dedicated to improving health. Co-founder, #radonc journal club, @Rad_Nation. Chair, @MassMedical Communications Committee","id_on_source":"subatomicdoc","tweeter_id":"88581667","geo":{"lt":42.63342,"ln":-71.31617,"country":"US"},"followers":15343},"tweet_id":"723868161808826368"},{"url":"http:\/\/twitter.com\/Nani6016\/statuses\/723868343262916608","license":"gnip","rt":["subatomicdoc"],"citation_ids":[4835329],"posted_on":"2016-04-23T13:37:16+00:00","author":{"name":"Dani Angel Sch\u00fctte","image":"https:\/\/pbs.twimg.com\/profile_images\/911189664140337152\/sx-TLaXh_normal.jpg","description":"Angel es mi apellido.\n Radiation therapy and nuclear medicine.\n\n Onc\u00f3logo radioter\u00e1pico y M\u00e9dico  Nuclear #radonc","id_on_source":"Nani6016","tweeter_id":"31317760","geo":{"lt":null,"ln":null},"followers":907},"tweet_id":"723868343262916608"},{"url":"http:\/\/twitter.com\/Rad_Nation\/statuses\/724191923867639808","license":"gnip","citation_ids":[4835329],"posted_on":"2016-04-24T11:03:04+00:00","author":{"name":"Radiation Nation","url":"http:\/\/radiationnation.com","image":"https:\/\/pbs.twimg.com\/profile_images\/2179212194\/Logo_normal.jpg","description":"Radiation Nation is dedicated to improving cancer care globally. Moderates #radonc journal club. Content by @subatomicdoc @BreastDocUK","id_on_source":"Rad_Nation","tweeter_id":"567395732","geo":{"lt":null,"ln":null},"followers":2666},"tweet_id":"724191923867639808"},{"url":"http:\/\/twitter.com\/Rad_Nation\/statuses\/724199989086433280","license":"gnip","citation_ids":[4835329],"posted_on":"2016-04-24T11:35:07+00:00","author":{"name":"Radiation Nation","url":"http:\/\/radiationnation.com","image":"https:\/\/pbs.twimg.com\/profile_images\/2179212194\/Logo_normal.jpg","description":"Radiation Nation is dedicated to improving cancer care globally. Moderates #radonc journal club. Content by @subatomicdoc @BreastDocUK","id_on_source":"Rad_Nation","tweeter_id":"567395732","geo":{"lt":null,"ln":null},"followers":2666},"tweet_id":"724199989086433280"},{"url":"http:\/\/twitter.com\/roentgen66\/statuses\/724200292179427328","license":"gnip","rt":["Rad_Nation"],"citation_ids":[4835329],"posted_on":"2016-04-24T11:36:19+00:00","author":{"name":"Virginia Ruiz","url":"http:\/\/www.radioncologa.com","image":"https:\/\/pbs.twimg.com\/profile_images\/3707494957\/3bdb03ab17f72fa5fcd7cff30d84adbe_normal.jpeg","description":"#yosoyradioncologo Madre de 2. Vocaci\u00f3n de #edoctor. Apoyo la necesidad de un toque m\u00e1s humano a la Medicina. I \u2764 Oncology #eHealth #socialnetworker","id_on_source":"roentgen66","tweeter_id":"263607999","geo":{"lt":42.35022,"ln":-3.67527,"country":"ES"},"followers":3125},"tweet_id":"724200292179427328"},{"url":"http:\/\/twitter.com\/Rad_Nation\/statuses\/724259915951443968","license":"gnip","citation_ids":[4835329],"posted_on":"2016-04-24T15:33:14+00:00","author":{"name":"Radiation Nation","url":"http:\/\/radiationnation.com","image":"https:\/\/pbs.twimg.com\/profile_images\/2179212194\/Logo_normal.jpg","description":"Radiation Nation is dedicated to improving cancer care globally. Moderates #radonc journal club. Content by @subatomicdoc @BreastDocUK","id_on_source":"Rad_Nation","tweeter_id":"567395732","geo":{"lt":null,"ln":null},"followers":2666},"tweet_id":"724259915951443968"},{"url":"http:\/\/twitter.com\/Rad_Nation\/statuses\/724322240960073730","license":"gnip","citation_ids":[4835329],"posted_on":"2016-04-24T19:40:54+00:00","author":{"name":"Radiation Nation","url":"http:\/\/radiationnation.com","image":"https:\/\/pbs.twimg.com\/profile_images\/2179212194\/Logo_normal.jpg","description":"Radiation Nation is dedicated to improving cancer care globally. Moderates #radonc journal club. Content by @subatomicdoc @BreastDocUK","id_on_source":"Rad_Nation","tweeter_id":"567395732","geo":{"lt":null,"ln":null},"followers":2666},"tweet_id":"724322240960073730"},{"url":"http:\/\/twitter.com\/HPB_surgery\/statuses\/741240864232505344","license":"gnip","citation_ids":[4835329],"posted_on":"2016-06-10T12:09:28+00:00","author":{"name":"HPB_surgery","image":"https:\/\/pbs.twimg.com\/profile_images\/643215676610490368\/deZWut4o_normal.png","description":"HPB focused literature - as its published","id_on_source":"HPB_surgery","tweeter_id":"2581464331","geo":{"lt":null,"ln":null},"followers":383},"tweet_id":"741240864232505344"}],"facebook":[{"title":"Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular...","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1523980617911925&id=1389966547980000","license":"public","citation_ids":[4835329],"posted_on":"2015-12-07T14:28:10+00:00","summary":"SBRT is a good first choice for large, inoperable HCC lesions compared to RFA; a retrospective study with 224 pts in JCO","author":{"name":"Radiosurgical Research Institute","url":"https:\/\/www.facebook.com\/1389966547980000","facebook_wall_name":"Radiosurgical Research Institute","image":"https:\/\/graph.facebook.com\/1389966547980000\/picture","id_on_source":"1389966547980000"}}],"news":[{"title":"Ablation, Radiotherapy Similarly Effective for Liver Cancer","url":"http:\/\/ct.moreover.com\/?a=23940752761&p=1pl&v=1&x=QZyTV9KH60_EKryi1mBzMg","license":"public","citation_ids":[4835329,4942131],"posted_on":"2015-12-31T20:35:17+00:00","summary":"Radiofrequency ablation (RFA) and stereotactic body radiotherapy (SBRT) appear to be effective local treatments for inoperable liver cancer, although SBRT may be slightly better for larger tumors (\u22652 cm), say researchers reporting a single-center\u2026","author":{"name":"Medscape","url":"http:\/\/medscape.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/055\/normal\/medscape.png?1369846939"}},{"title":"Schonende Behandlung bei fortgeschrittenem Krebs","url":"http:\/\/ct.moreover.com\/?a=25900639455&p=1pl&v=1&x=mWSS3yrsDh3uWVfdZBNIUw","license":"public","citation_ids":[4835329],"posted_on":"2016-03-18T13:42:49+00:00","summary":"Artikeltext: Den Patienten bleiben die Strapazen einer Operation erspart und die Behandlung ist schonender als eine Radiofrequenztherapie, bei der eine Sonde in die Leber eingef\u00fchrt werden muss.","author":{"name":"Biermann Medizin","url":"http:\/\/www.biermann-medizin.de\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/421\/normal\/Screen_Shot_2016-02-02_at_15.17.22.png?1454426255"}}],"googleplus":[{"url":"https:\/\/plus.google.com\/103728091485283552669\/posts\/JUSPtezxVa7","license":"public","citation_ids":[4835329],"posted_on":"2015-12-12T06:38:03+00:00","summary":"Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma Abstract Purpose Data guiding selection of nonsurgical treatment of hepatocellular carcinoma (HCC) are lacking. We therefore compared outcomes between ste","author":{"name":"\u4e2d\u6751\u592a\u7950","url":"https:\/\/plus.google.com\/103728091485283552669","image":"https:\/\/lh3.googleusercontent.com\/-XdUIqdMkCWA\/AAAAAAAAAAI\/AAAAAAAAAAA\/4252rscbv5M\/photo.jpg?sz=50","id_on_source":"103728091485283552669"}},{"title":"SBRT is a good first choice for large, inoperable HCC lesions compared to RFA; a retrospective study...","url":"https:\/\/plus.google.com\/+RriusOrgRadiosurgeryResearch\/posts\/Hv2EaoFG2KC","license":"public","citation_ids":[4835329],"posted_on":"2015-12-07T21:31:19+00:00","summary":"SBRT is a good first choice for large, inoperable HCC lesions compared to RFA; a retrospective study... SBRT is a good first choice for large, inoperable HCC lesions compared to RFA; a retrospective study with 224 pts in JCO\ufeff Outcomes After Stereotactic Bo"}]}}